{"id":"abatacept-sc","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Infection (upper respiratory, urinary tract)"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Dizziness"},{"rate":"5-10","effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Abatacept (CTLA4-Ig) binds to CD80 and CD86 molecules on antigen-presenting cells, preventing their interaction with CD28 on T cells. This blocks the second signal needed for T cell activation, thereby suppressing the adaptive immune response. The subcutaneous formulation allows for patient self-administration while maintaining the same mechanism of action as the intravenous form.","oneSentence":"Abatacept is a fusion protein that inhibits T cell activation by blocking the CD80/CD86 costimulatory signal required for full T cell engagement.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:47:23.258Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Polyarticular juvenile idiopathic arthritis"},{"name":"Psoriatic arthritis"},{"name":"Ankylosing spondylitis"}]},"trialDetails":[{"nctId":"NCT07161999","phase":"PHASE2","title":"Study of COYA 302 for the Treatment of ALS","status":"RECRUITING","sponsor":"Coya Therapeutics","startDate":"2025-10-01","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":120},{"nctId":"NCT03929601","phase":"PHASE2","title":"Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2023-10-30","conditions":"Type 1 Diabetes Mellitus","enrollment":74},{"nctId":"NCT03457142","phase":"PHASE2","title":"Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2018-09-11","conditions":"Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma","enrollment":15},{"nctId":"NCT04909801","phase":"PHASE3","title":"A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2021-09-15","conditions":"Rheumatoid Arthritis","enrollment":338},{"nctId":"NCT04066114","phase":"PHASE1, PHASE2","title":"Treg Modulation With CD28 and IL-6 Receptor Antagonists","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-11","conditions":"Living-Donor Kidney Transplant, Kidney Transplant Recipients","enrollment":24},{"nctId":"NCT04118153","phase":"EARLY_PHASE1","title":"Early Markers of Disease and Response to Therapy","status":"COMPLETED","sponsor":"Sandra Lord, MD","startDate":"2021-03-05","conditions":"Type 1 Diabetes","enrollment":60},{"nctId":"NCT02971683","phase":"PHASE3","title":"Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-05-04","conditions":"Polymyositis, Dermatomyositis, Autoimmune Necrotizing Myopathy","enrollment":149},{"nctId":"NCT01844518","phase":"PHASE3","title":"Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-08-30","conditions":"Active Polyarticular Juvenile Idiopathic Arthritis","enrollment":219},{"nctId":"NCT03188081","phase":"","title":"A Study to Investigate the Effectiveness of an Education Support Program on Medication Adherence in Italian Real Life Rheumatoid Arthritis (RA) Patients Treated With Subcutaneous (SC) Abatacept","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-08-02","conditions":"Rheumatoid Arthritis","enrollment":171},{"nctId":"NCT02335606","phase":"","title":"Real World Effectiveness of Abatacept in Rheumatoid Arthritis Patients: a Prospective, Single-arm, Open-label, Multi-center Observational Study in Taiwan","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-08-06","conditions":"Rheumatoid Arthritis","enrollment":213},{"nctId":"NCT02090556","phase":"","title":"Long-term Experience With Abatacept SC in Routine Clinical Practice","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-03-26","conditions":"Rheumatoid Arthritis","enrollment":2954},{"nctId":"NCT03669861","phase":"PHASE2","title":"Safety and Efficacy of Abatacept in IgG4-Related Disease","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2018-11-13","conditions":"IgG4-related Disease","enrollment":10},{"nctId":"NCT02504268","phase":"PHASE3","title":"Effects of Abatacept in Patients With Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-09-03","conditions":"Rheumatoid Arthritis","enrollment":994},{"nctId":"NCT01557374","phase":"PHASE4","title":"TOward the Lowest Effective DOse of Abatacept or Tocilizumab","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2012-04","conditions":"Rheumatoid Arthritis","enrollment":232},{"nctId":"NCT02053727","phase":"NA","title":"Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background","status":"WITHDRAWN","sponsor":"University of California, Los Angeles","startDate":"2014-07","conditions":"Rheumatoid Arthritis, Chronic Hepatitis B","enrollment":""},{"nctId":"NCT03288584","phase":"","title":"Effects of Interleukin-6 Inhibition on Vascular, Endothelial and Left Ventricular Function in Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"University of Athens","startDate":"2017-10-27","conditions":"Rheumatoid Arthritis, Inflammation","enrollment":60},{"nctId":"NCT02161406","phase":"PHASE2","title":"A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis","status":"COMPLETED","sponsor":"Dinesh Khanna, MD, MS","startDate":"2014-09","conditions":"Diffuse Cutaneous Systemic Sclerosis","enrollment":88},{"nctId":"NCT02067910","phase":"PHASE3","title":"Efficacy and Safety of Abatacept in Patients With Primary Sjögren's Syndrome","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2014-08","conditions":"Sjögren's Syndrome","enrollment":80},{"nctId":"NCT02018042","phase":"PHASE2","title":"An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata","status":"COMPLETED","sponsor":"Columbia University","startDate":"2013-09","conditions":"Alopecia Areata","enrollment":15},{"nctId":"NCT03274141","phase":"","title":"Comparing the Effectiveness of a Treat-to-target (T2T) Disease Management Strategy vs. Routine Care (RC) in Adult Patients With Moderate to Severe Rheumatoid Arthritis (RA) Treated With Subcutaneous Abatacept (Orencia - SC)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-10-31","conditions":"Rheumatoid Arthritis","enrollment":281},{"nctId":"NCT02632890","phase":"","title":"Assessment of the Effectiveness of IV and SC Abatacept (Orencia) Patient Alert Cards in Patients With Rheumatoid Arthritis in a Sample of EU Countries","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2016-11-29","conditions":"Rheumatoid Arthritis","enrollment":203},{"nctId":"NCT01351480","phase":"PHASE3","title":"Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients","status":"COMPLETED","sponsor":"Arthritis & Rheumatic Disease Specialties Research","startDate":"2011-06","conditions":"Rheumatoid Arthritis","enrollment":34},{"nctId":"NCT02027298","phase":"PHASE2","title":"Abatacept for Patients With Inflammatory Arthritis Associated With Sjögren's Syndrome: an Open-Label Phase II Study","status":"WITHDRAWN","sponsor":"The Cleveland Clinic","startDate":"2013-11","conditions":"Primary Sjogren's Syndrome, Secondary Sjogren's Syndrome, Inflammatory Arthritis","enrollment":""},{"nctId":"NCT02805010","phase":"PHASE1","title":"Pharmacokinetics, Safety and Tolerability Study of Single Dose of Abatacept 125mg Administered Subcutaneously","status":"UNKNOWN","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2016-10","conditions":"Rheumatoid Arthritis (RA)","enrollment":22},{"nctId":"NCT00569803","phase":"PHASE1","title":"Subcutaneous Pharmacokinetics of Belatacept","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-12","conditions":"Transplantation","enrollment":153},{"nctId":"NCT02722694","phase":"PHASE3","title":"A Phase 3 Study of Abatacept in Chinese Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate","status":"UNKNOWN","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2016-08","conditions":"Rheumatoid Arthritis (RA)","enrollment":360},{"nctId":"NCT02598466","phase":"","title":"Patient-Reported Efficacy of Subcutaneous (SC) Abatacept in Rheumatoid Arthritis (RA) - South Africa","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-07","conditions":"Rheumatoid Arthritis","enrollment":69},{"nctId":"NCT01142726","phase":"PHASE3","title":"Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-12","conditions":"Rheumatoid Arthritis","enrollment":511},{"nctId":"NCT01890473","phase":"PHASE1","title":"Study to Characterize the Pharmacokinetics of a Single Dose of SC Abatacept 125 mg Using the BD Autoinjector or the Prefilled Syringe","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-07","conditions":"Rheumatoid Arthritis","enrollment":356},{"nctId":"NCT00559585","phase":"PHASE3","title":"Methotrexate-Inadequate Response Study","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-01","conditions":"Rheumatoid Arthritis (RA)","enrollment":2492},{"nctId":"NCT00547521","phase":"PHASE3","title":"Phase IIIB Subcutaneous Abatacept Monotherapy Study","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-12","conditions":"Rheumatoid Arthritis (RA)","enrollment":119},{"nctId":"NCT01846975","phase":"PHASE4","title":"Introducing a Single IV Abatacept Treatment in RA Patients Currently Receiving Weekly SC Abatacept to Simulate a Holiday","status":"COMPLETED","sponsor":"Rüdiger B. Müller","startDate":"2013-05","conditions":"Rheumatoid Arthritis","enrollment":49},{"nctId":"NCT01917058","phase":"PHASE2","title":"A Clinical Trial to Evaluate the Efficacy of Abatacept in Moderate to Severe Alopecia Areata","status":"WITHDRAWN","sponsor":"Columbia University","startDate":"2013-08","conditions":"Alopecia Areata","enrollment":""},{"nctId":"NCT00254293","phase":"PHASE1, PHASE2","title":"Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2006-01","conditions":"Rheumatoid Arthritis","enrollment":87},{"nctId":"NCT01001832","phase":"PHASE2, PHASE3","title":"Efficacy, Pharmacokinetics, Safety, and Immunogenicity Study of Abatacept Administered Subcutaneously to Treat Rheumatoid Arthritis in Japanese Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-12","conditions":"Rheumatoid Arthritis","enrollment":118},{"nctId":"NCT01173120","phase":"PHASE3","title":"Methotrexate - Inadequate Response Device Sub-Study","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-11","conditions":"Rheumatoid Arthritis (RA)","enrollment":62}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Subcutaneous Abatacept","Orencia"],"phase":"phase_3","status":"active","brandName":"Abatacept SC","genericName":"Abatacept SC","companyName":"University Medical Center Groningen","companyId":"university-medical-center-groningen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Abatacept is a fusion protein that inhibits T cell activation by blocking the CD80/CD86 costimulatory signal required for full T cell engagement. Used for Rheumatoid arthritis, Polyarticular juvenile idiopathic arthritis, Psoriatic arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}